FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to biotechnology, specifically to use of recombinant water-soluble domain Lynx1 with SEQ ID NO: 1 for growth inhibition by carcinoma, and can be used in medicine.
EFFECT: use of the water-soluble domain of Lynx1 in concentrations of 10 nM to 10 mc enables cell growth inhibition by lung carcinoma.
3 cl, 4 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF RECOMBINANT ANALOGUE OF HUMAN PROTEIN SLURP-1 IN COMBINATION WITH CYTOSTATICS OR PROTEASOME INHIBITOR PRODUCTS FOR INHIBITING GROWTH OF CARCINOMAS | 2020 |
|
RU2751132C1 |
| PEPTIDE HAVING ACTIVITY OF HUMAN SLURP-1 PROTEIN AND ITS APPLICATION FOR SUPPRESSION OF GROWTH OF CARCINOMA AND GLIOMA, PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF GROWTH OF CARCINOMA AND GLIOMA, AND METHOD FOR SUPPRESSION OF GROWTH OF CARCINOMA AND GLIOMA USING THE SPECIFIED PEPTIDE | 2022 |
|
RU2792364C1 |
| MODIFIED CELLS WITH CHIMERIC ANTIGEN RECEPTOR FOR TREATING CANCER EXPRESSING CLDN6 | 2020 |
|
RU2826058C2 |
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN 6 OR CLAUDIN 18.2 AND CD3 FOR THE TREATMENT OF ONCOLOGICAL DISEASES WITH CLAUDIN EXPRESSION | 2017 |
|
RU2798988C2 |
| METHODS FOR TREATING CANCER, INCLUDING TIGIT-BINDING AGENTS | 2017 |
|
RU2765410C2 |
| ANTIBODIES FOR TREATING CANCER, IN WHICH CLAUDIN 6 IS EXPRESSED | 2012 |
|
RU2816850C2 |
| DIAGNOSTICS AND TREATMENT OF CANCER ASSOCIATED WITH CANCER STEM CELLS | 2014 |
|
RU2749867C2 |
| ANTIBODIES USEFUL IN DIAGNOSING CANCER | 2018 |
|
RU2815883C1 |
| THERAPEUTIC BIOPREPARATION FOR TREATING HEPATOCELLULAR CARCINOMA | 2014 |
|
RU2739218C2 |
